Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment

被引：28

作者：

Tozuka, Takehiro ^{[1
,2
]}

Kitazono, Satoru ^{[1
]}

Sakamoto, Hiroaki ^{[1
]}

Yoshida, Hiroshi ^{[1
]}

Amino, Yoshiaki ^{[1
]}

Uematsu, Shinya ^{[1
]}

Yoshizawa, Takahiro ^{[1
]}

Hasegawa, Tsukasa ^{[1
]}

Ariyasu, Ryo ^{[1
]}

Uchibori, Ken ^{[1
]}

Yanagitani, Noriko ^{[1
]}

Horai, Takeshi ^{[1
]}

Seike, Masahiro ^{[2
]}

Gemma, Akihiko ^{[2
]}

Nishio, Makoto ^{[1
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan

[2] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan

来源：

LUNG CANCER | 2020年 / 144卷

关键词：

Immune checkpoint inhibitor; Anti PD-1/PD-L1 antibody; Docetaxel; Ramucirumab; Vascular endothelial growth factor; CELL LUNG-CANCER; RESPONSE RATES; CHEMOTHERAPY; INHIBITORS;

D O I：

10.1016/j.lungcan.2020.04.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: : Docetaxel (DTX) efficacy increases in patients with non-small cell lung cancer (NSCLC) who had received anti-programmed cell death-1/ligand 1 (anti-PD-1/L1) therapy. However, the effect of ramucirumab (Ram) on DTX efficacy following anti-PD-1/L1 therapy is unknown. Here, we aimed to evaluate the effect of Ram on DTX efficacy following anti-PD-1/L1 therapy. Materials and methods: This retrospective study included 99 patients with NSCLC, who were divided into those who had (pre-ICI group) or had not (no-ICI group) received anti-PD-1/L1 antibody before DTX. Both groups were then treated with DTX or DTX plus Ram (DTX/Ram). Patient characteristics were compared between the DTX and DTX/Ram groups and adjusted with inverse probability of treatment weighting using propensity scores and the following confounding variables: age, sex, performance status, smoking status, histology, driver mutation, and line of treatment. We compared DTX/Ram and DTX in terms of efficacy in both the pre-ICI and no-ICI groups. Results: In the pre-ICI group, 18 and 21 patients received DTX and DTX/Ram, respectively. In the no-ICI group, 35 and 25 patients received DTX and DTX/Ram. In the no-ICI group, progression-free survival (PFS) and overall survival (OS) were not significantly different between DTX/Ram- and DTX-treated patients (median PFS, 2.6 versus 1.6 months; p = 0.30, median OS; 8.2 versus 8.0 months; p = 0.30). In the pre-ICI group, PFS was significantly longer in DTX/Ram-treated than in DTX-treated patients (median, 5.9 versus 2.8 months; p = 0.03). Hazard ratio for disease progression or death was 0.75 (95% confidence interval, 0.20-0.96). The OS of DTX/Ram-treated patients tended to be longer than that of DTX-treated patients (median, 19.8 versus 8.6 months; p = 0.10). Conclusions: DTX efficacy following anti-PD-1/L1 therapy may be enhanced by Ram. Further studies are needed to validate the efficacy of inhibiting the vascular endothelial growth factor pathway following anti-PD-1/L1 therapy.

引用

页码：71 / 75

页数：5

共 19 条

[1] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[2] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

[3] Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses [J].

Fricke, Ingo ;

Mirza, Noweeda ;

Dupont, Jakob ;

Lockhart, Craig ;

Jackson, Autumn ;

Lee, Ji-Hyun ;

Sosman, Jeffrey A. ;

Gabrilovich, Dmitry I. .

CLINICAL CANCER RESEARCH, 2007, 13 (16) :4840-4848

[4] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[5] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[6] Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study [J].

Gettinger, Scott ;

Horn, Leora ;

Jackman, David ;

Spigel, David ;

Antonia, Scott ;

Hellmann, Matthew ;

Powderly, John ;

Heist, Rebecca ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Geese, William J. ;

Yoon, Dennis ;

Li, Ang ;

Brahmer, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1675-+

[7] Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation [J].

Ghiringhelli, F ;

Puig, PE ;

Roux, S ;

Parcellier, A ;

Schmitt, E ;

Solary, E ;

Kroemer, G ;

Martin, F ;

Chauffert, B ;

Zitvogel, L .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) :919-929

[8] Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination ChemotherapyPrevious Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy [J].

Harada, Daijiro ;

Takata, Kenji ;

Mori, Shunta ;

Kozuki, Toshiyuki ;

Takechi, Yoshika ;

Moriki, Satoko ;

Asakura, Yumi ;

Ohno, Takayuki ;

Nogami, Naoyuki .

ANTICANCER RESEARCH, 2019, 39 (09) :4987-4993

[9] Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial [J].

Herbst, Roy S. ;

Arkenau, Hendrik-Tobias ;

Santana-Davila, Rafael ;

Calvo, Emiliano ;

Paz-Ares, Luis ;

Cassier, Philippe A. ;

Bendell, Johanna ;

Penel, Nicolas ;

Krebs, Matthew G. ;

Martin-Liberal, Juan ;

Isambert, Nicolas ;

Soriano, Andres ;

Wermke, Martin ;

Cultrera, Jennifer ;

Gao, Ling ;

Widau, Ryan C. ;

Mi, Gu ;

Jin, Jin ;

Ferry, David ;

Fuchs, Charles S. ;

Petrylak, Daniel P. ;

Chau, Ian .

LANCET ONCOLOGY, 2019, 20 (08) :1109-1123

[10]

Jiang Q, 2017, ONCOTARGET, V9, P7672

← 1 2 →